Industry officials said the U.S. Food and Drug Administration on April 1 approved Lilly’s oral glucagon-like peptide-1, or GLP-1, obesity drug Foundayo (active ingredient: orforglipron). The agency’s decision came 50 days after the application, an unusually fast timeline that industry watchers said underscores regulators’ priority on obesity treatments.
Novo Nordisk entered first with an oral version marketed as “Wegovy pill.” Novo’s product requires dosing on an empty stomach and limits on water intake around the time of use, while Lilly says Foundayo can be taken without restrictions on food or timing. Lilly is promoting it as a GLP-1 tablet that can be taken at any time.
Pricing is set at a similar level. Lilly priced Foundayo roughly in line with oral Wegovy: $25 a month for insured patients and $149 for those without insurance. That is far below the monthly cost of existing injectable drugs, which can run into the millions of won in Korea.
Weekly injections remain the standard in obesity care, but oral drugs could spread quickly in early-stage treatment because they are easier to take, the industry said. The result, officials said, is likely a clearer split in choices based on effectiveness, convenience and lifestyle.
On weight loss, injections still lead. Lilly’s injectable Zepbound showed average weight loss of 15 to 21 kilograms over 72 weeks, and about one-third of patients on the highest dose lost at least 26 kilograms.
Lilly’s clinical data showed participants taking the highest dose of Foundayo lost an average of 12 kilograms over the same period. Because it is taken daily, results may vary, but the pill could broaden access among patients who are reluctant to use injections, the company and industry officials said.
An industry official called the shift a turning point as obesity drugs move from “specialty therapies” toward “mass-market consumer products,” adding that oral drugs are clearly gaining momentum but choices will differ by effectiveness, convenience and lifestyle. Over time, the market is likely to split into two tracks, the official said.
Lilly plans to begin shipping Foundayo on April 6 through its LillyDirect platform, aiming to secure early demand via U.S. retail pharmacies and telehealth providers. The company has submitted Foundayo approval applications in more than 40 countries, starting with the United States.
Some countries that have been cautious about reimbursing obesity drugs because of high prices may revisit coverage as relatively cheaper oral options emerge, industry officials said. Another official said the market is expanding alongside growth in chronic-disease management, and that insurance and reimbursement talks are likely to accelerate.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.